Statistics from Altmetric.com
The vascular endothelium is a monolayer of cells between the vessel lumen and the vascular smooth muscle cells. Far from being inert, it is metabolically active and produces a variety of vasoactive mediators. Among these mediators, endothelial derived nitric oxide is essential in the maintenance of vascular homeostasis, and defects in the L-arginine: nitric oxide pathway have been implicated in a variety of cardiovascular diseases.
From EDRF to nitric oxide
In 1980, Furchgott and Zawadzki showed that the presence of vascular endothelial cells is essential for acetylcholine to induce relaxation of isolated rabbit aorta.1 If the vascular endothelium was removed, the blood vessel failed to relax in response to acetylcholine but still responded to glyceryl trinitrate. This endothelium dependent relaxation of vascular smooth muscle to acetylcholine is mediated by an endogenous mediator initially named endothelium derived relaxing factor (EDRF),1 which was subsequently identified as nitric oxide.2 ,3
L-arginine: nitric oxide pathway
Endothelium derived nitric oxide is synthesised from the amino acid L-arginine by the endothelial isoform of nitric oxide synthase, yielding L-citrulline as a byproduct.4 Nitric oxide is labile with a short half life (< 4 seconds in biological solutions). It is rapidly oxidised to nitrite and then nitrate by oxygenated haemoglobin before being excreted into the urine.4 Several co-factors are required for nitric oxide biosynthesis. These include nicotinamide adenine dinucleotide phosphate (NADPH), flavin mononucleotide, flavin adenine dinucleotide, tetrahydrobiopterin (BH4), and calmodulin. Once synthesised, the nitric oxide diffuses across the endothelial cell membrane and enters the vascular smooth muscle cells where it activates guanylate cyclase, leading to an increase in intracellular cyclic guanosine-3',5-monophosphate (cGMP) concentrations4 (fig 1). As a second messenger, cGMP mediates many of the biological effects of nitric oxide including the control of vascular tone and platelet function. In addition, nitric oxide has other molecular targets which include haem or other iron centred proteins, DNA, and thiols. These additional reactions may mediate changes in functions of certain key enzymes or ion channels. Nitric oxide also interacts with enzymes of the respiratory chain including complex I and II, and aconitase, and through these effects alters tissue mitochondrial respiration. Interaction of nitric oxide with superoxide anion can attenuate physiological responses mediated by nitric oxide and produce irreversible inhibitory effects on mitochondrial function as a result of the formation of peroxynitrite (ONOO−), a powerful oxidant species.
Nitric oxide synthase isoforms
Three isoforms of nitric oxide synthase (NOS) have been identified: the endothelial isoform (eNOS), neuronal isoform (nNOS), and macrophage or inducible isoform (iNOS). All three NOS isoforms play distinct roles in the regulation of vascular tone (fig 2). The genes encoding eNOS, nNOS, and iNOS are located on chromosome 7, 12, and 17, respectively.5 Whereas eNOS and nNOS are normal constituents of healthy cells, iNOS is not usually expressed in vascular cells and its expression is seen mainly in conditions of infection or inflammation.
Biological effects of nitric oxide
Nitric oxide and the vasculature
Endothelium derived nitric oxide is a potent vasodilator in the vasculature, and the balance between nitric oxide and various endothelium derived vasoconstrictors and the sympathetic nervous system maintains blood vessel tone. In addition, nitric oxide suppresses platelet aggregation, leucocyte migration, and cellular adhesion to the endothelium, and attenuates vascular smooth muscle cell proliferation and migration. Furthermore, nitric oxide can inhibit activation and expression of certain adhesion molecules, and influence production of superoxide anion. Loss of endothelium derived nitric oxide would be expected to promote a vascular phenotype more prone to atherogenesis, a concept supported by studies in experimental animals.6
The L-arginine: nitric oxide pathway
Nitric oxide is synthesised from L-arginine to yield citrulline
Co-factors required for nitric synthesis:
nicotinamide adenine dinucleotide phosphate (NADPH)
flavin adenine dinucleotide
Enzymes responsible for nitric oxide synthesis:
endothelial nitric oxide synthase (expressed in normal cells) (eNOS)
neuronal nitric oxide synthase (expressed in normal cells) (nNOS)
inducible nitric oxide synthase (expressed during infection/inflammation) (iNOS)
Nitric oxide activates guanylate cyclase in vascular smooth muscle cells to synthesise cyclic guanosine-3',5-monophosphate (cGMP) which causes many of its biological effects
Nitric oxide release from the vascular endothelium
There is a continuous basal synthesis of nitric oxide from the vascular endothelium to maintain resting vascular tone. A number of chemical and physical stimuli may activate eNOS and lead to increased nitric oxide production.
Basal nitric oxide release
The synthesis of nitric oxide in vascular endothelial cells in culture or intact vascular tissue can be inhibited by NGmonomethyl-L-arginine (L-NMMA), an analogue of L-arginine in which one of the guanidino nitrogen atoms is methylated. This inhibitory effect of L-NMMA is readily reversed by L-arginine.7 L-NMMA and similar substrate based inhibitors have been used to examine the role of nitric oxide in various vascular beds in vitro and in both human and animal models.
In rings of rabbit aorta, L-NMMA causes significant endothelium dependent contraction. Intravenous infusion of L-NMMA into experimental animals induces a dose related increase in blood pressure which is reversed by intravenous administration of L-arginine, and in the human forearm vasculature infusion of L-NMMA into the brachial artery causes substantial dose dependent vasoconstriction. Thus continuous generation of nitric oxide is crucial in maintaining peripheral vasodilatation in humans7 (fig 3). This basal nitric oxide mediated dilatation has been seen in every other arterial bed studied including cerebral, pulmonary, renal, and coronary vasculature. In contrast, in the venous system inhibitors of NOS do not lead to an increase in basal tone in a variety of venous preparations from animals or humans,8 suggesting that basal nitric oxide production does not have a major role in the maintenance of the resting tone in most veins. In conduit vessels, there is some basal nitric oxide mediated dilatation but it appears to be less than that seen in resistance vessels.
Agonist stimulated nitric oxide release
Many chemical substances such as acetylcholine, bradykinin, serotonin, and substance P are able to induce endothelium dependent vasodilatation. In rings of rabbit aorta, endothelium dependent relaxation induced by acetylcholine, calcium ionophore (A23187) or substance P is inhibited by L-NMMA. This provides in vitro evidence that vasorelaxation induced by endothelium dependent agonists is nitric oxide mediated. L-NMMA also attenuates the hypotensive effect of acetylcholine in vivo in animals. However, the blockade is far from complete and there is now growing evidence for additional mechanisms underlying endothelium dependent responses to acetylcholine, particularly in resistance vessels. Similarly in humans, L-NMMA inhibits agonist stimulated relaxation in resistance,7conduit, and venous vessels in vivo. However, the degree of inhibition to agonist dependent dilatation varies between vascular beds, and mechanisms (for example, prostaglandins and endothelium derived hyperpolarising factors) other than that mediated by nitric oxide appear to be involved.
Physical forces and nitric oxide release
Haemodynamic shear stress exerted by the viscous drag of flowing blood is an important physiological stimulus in the regulation of nitric oxide release from the endothelium. The mechanisms of shear stress induced nitric oxide release is complex, involving (1) extremely rapid initiation via ion channel activation, and (2) subsequent events related to signalling pathway activation such as phosphorylation of eNOS protein and increased expression of eNOS mRNA and protein. These complex events allow rapid and short lasting as well as slow onset and sustained vasodilatation in response to changes in shear stress.
Ultra-quick: ion channels
Numerous in vitro studies have provided strong evidence that ion channels—including certain calcium, potassium, and chloride ion channels—open seconds after exposure to haemodynamic shear. Application of shear stress to bovine aortic endothelial cells by fluid perfusion led to an immediate large increase in intracellular free calcium within one minute followed by a rapid decline. Notably, the increase in intracellular calcium occurs only in response to pulsatile flow and not to steady flow. The detection of potassium selective current with whole cell patch clamp recordings of arterial endothelial cells suggests activation of a distinct potassium channel in response to shear stress. Recently, a flow activated, chloride selective membrane current in vascular endothelial cells, distinct from the potassium current, was demonstrated. The balance between anionic and cationic current determines the net membrane potential and the subsequent change in calcium that alters eNOS activation and nitric oxide output.
Mechanical activation of eNOS as induced by shear stress occurs also via phosphorylation and the effect is independent of intracellular calcium concentrations. It has been shown that in response to shear stress, the serine/threonine protein kinase B (Akt) directly phosphorylates and activates eNOS with a maximal increase up to sixfold after one hour of exposure to shear stress. The stimulation of Akt phosphorylation by shear stress appears to be mediated by phosphoinositide 3-OH kinase.
Slow: increased transcription
Shear stress also stimulates eNOS gene transcription to maintain long term nitric oxide production. Application of shear stress for three hours resulted in an induction of eNOS mRNA in a dose dependent manner in both bovine and human aortic endothelial cells.
These in vitro experimental data demonstrate the complexity of short medium and long term regulation of nitric oxide release in response to shear stress.
Loss of nitric oxide and predisposition to atherogenesis
A reduction in nitric oxide activity (manifested as impaired endothelial dependent vasodilatation) occurs very early in experimental and human hypercholesterolaemia, even before any structural changes in the vascular wall. In some cases, the impaired endothelial dependent vasodilatation appears to be reversed with L-arginine.9The action that nitric oxide normally has as an antiatherogenic factor is supported by studies of long term NOS inhibition. Aortic rings from rabbits fed with cholesterol rich diet showed impaired endothelial dependent vasorelaxation to acetylcholine. Furthermore, blockade of nitric oxide with nitro-L-arginine methylester (L-NAME) causes structural changes with development of greater lesion surface area in the aorta of hypercholesterolaemic rabbits.
Endothelial dysfunction in established cardiovascular disease
Impaired endothelium dependent vasorelaxation to acetylcholine occurs in experimental models of atherosclerosis. In these studies, relaxation to endothelium independent nitric oxide donors such as glyceryl trinitrate and sodium nitroprusside was unaffected, indicating selective impairment of the L-arginine–nitric oxide pathway rather than a generalised reduced vascular smooth muscle cell response to nitric oxide. Similar findings were also confirmed in human coronary and peripheral circulation in vivo.10 In patients with early coronary artery disease, abnormal responses to acetylcholine were found even in angiographically normal segments of coronary artery. Similarly, in patients with established coronary artery disease, endothelial dysfunction in the peripheral vessels as assessed by flow mediated dilatation is impaired. This impairment correlates with the extent of the coronary artery disease.
Chronic heart failure
Chronic heart failure (CHF) is characterised by a reduced vasodilator response to exercise and increased vasoconstriction; this is primarily a result of an imbalance between endothelium derived vasodilator and constrictor substances. There is general agreement that in CHF synthesis of endothelin-1, a potent vasoconstrictor, is greatly increased and this may contribute to the characteristic haemodynamic abnormalities. However, it remains unclear whether nitric oxide synthesis is decreased in CHF. The fact that endothelium dependent vasodilator response to acetylcholine, methacholine, and serotonin11 is attenuated in peripheral resistance vessels suggests a reduction in agonist stimulated nitric oxide release. In contrast, response to L-NMMA appears to be either unchanged or even paradoxically exaggerated in CHF. This could be partially explained by an increased basal nitric oxide synthesis in the face of increased vasoconstrictor generation. Interestingly, endothelium independent vasodilator response to nitric oxide donors may also be attenuated,11 suggesting that vascular smooth muscle sensitivity to nitric oxide might be reduced, with the degree of attenuation correlating with the severity of CHF. It is possible that the underlying mechanism relates to increased vascular generation of superoxide anion (O2 −) that inactivates nitric oxide.
Treatment of CHF with angiotensin converting enzyme (ACE) inhibitors has been shown to improve endothelium dependent vasodilatation induced by cholinergic stimuli. Furthermore, in a randomised, placebo controlled study of patients with moderate to severe CHF, spironolactone increased vasodilator response to acetylcholine with an associated increase in vasoconstriction to L-NMMA, suggesting enhanced basal nitric oxide mediated dilatation following spironolactone treatment. Whether these beneficial effects on endothelial nitric oxide contribute to the favourable outcome remains to be determined.
Endothelial dysfunction and risk factors for coronary heart disease
Experimentally induced hyperlipidaemia by either a fatty meal or intralipid infusion impairs flow mediated dilatation (FMD). In patients with hypercholesterolemia, endothelium dependent vasodilatation in both coronary and peripheral vessels is impaired before the development of clinical atherosclerosis.9 ,12 Restoration of normal or near normal endothelium dependent vasodilatation in the forearm resistance vessels of hypercholesterolaemic subjects can be achieved after six months of lipid lowering treatment. Interestingly, reduced vasodilatation in response to acetylcholine has also been seen in patients with raised triglyceride but normal low density lipoprotein (LDL) cholesterol concentrations. In patients with familial combined hyperlipidaemia, lipid lowering treatment improved forearm blood flow in response to serotonin. Finally, raised Lp(a) lipoprotein appears to enhance acetylcholine and cold pressor coronaryconstrictor responses in patients with normal coronary arteries on angiography and impairs basal nitric oxide production in forearm resistance vessels. Thus, there is compelling evidence to indicate that endothelial function is impaired by hyperlipidaemia. However, recently the reversibility of this defect in coronary arteries has been called into question.
Substantial evidence from animal and human studies indicates that acetylcholine induced relaxation is impaired in patients with hypertension. However, no difference was found in endothelium dependent vasodilator response to acetylcholine or carbachol between patients with essential hypertension and matched normotensive controls in at least one study. This may be because of differences in methodology and in population subgroups in this heterogeneous condition. There is, however, evidence that basal nitric oxide synthesis is reduced in essential hypertension and that vasoconstrictor response to L-NMMA is reduced in untreated hypertension, although again this has not been a universal finding.13 Current data would be most consistent with hypertension causing a decrease in nitric oxide mediated dilatation rather than the loss of nitric oxide causing essential hypertension. This notion is supported by the observation that impaired endothelium dependent vasodilatation in essential hypertension can be restored with antihypertensive treatment,13 and that endothelium dependent vasodilatation is impaired following acute elevation of blood pressure in normotensive subjects.
There is considerable controversy regarding the extent of endothelial dysfunction that occurs in type 1 diabetes mellitus, as endothelial function studies in both animal and human models of type 1 diabetes have produced conflicting results.14 For example, agonist stimulated, endothelium dependent vasodilatation has been found to be either impaired or unchanged. Endothelial function may be modulated by several factors associated with diabetes such as the degree of acute hyperglycaemia, chronicity of hyperglycaemia (disease duration), accumulation of advanced glycosylated end products, insulin concentrations, and diabetic complications such as autonomic neuropathy and microalbuminuria. Variation in these factors between studies may in part explain the conflicting results. At present, there is no clear consensus about the level at which the disease might alter nitric oxide signalling. Most data would be consistent with a reduced responsiveness to nitric oxide in type 1 diabetes, and large scale definitive studies in the future would be required to show whether this is the case.
Vascular studies in type 2 diabetes have generally shown an impaired muscarinic, agonist stimulated, endothelium dependent response as well as an impaired endothelium independent response, although the impaired endothelium independent response was not confirmed by other investigators. Interestingly, it has recently been shown that even normoglycaemic subjects who are prone to develop type 2 diabetes and insulin resistance syndrome, such as those characterised by previous gestational diabetes and low birth weight, exhibit impaired FMD. This has led to the suggestion that endothelial dysfunction may precede the development of type 2 diabetes.
Raised plasma homocysteine is thought to be an independent risk factor for coronary heart disease, and this may be mediated by endothelial dysfunction. Acute methionine induced hyperhomocysteinaemia impairs endothelium dependent FMD in healthy subjects which can be reversed by folic acid supplementation. Impaired FMD has also been found in chronic hyperhomocysteinaemia and homocysteinuric children. The concentration of plasma homocysteine associated with endothelial dysfunction in these in vivo human studies were several folds higher than the normal range. Recently, it has been shown that even mild physiological increments in plasma homocysteine concentrations were sufficient to impair endothelial function.
Links between risk factors and atherogenesis
In addition to various disease states, endothelium dependent vasodilatation is also impaired in old age,15 and in young healthy subjects with a family history of premature coronary heart disease and cigarette smoking. The age related endothelial dysfunction may partially explain the increased cardiovascular risk in the elderly. In asymptomatic young smokers, impairment of endothelium dependent vasodilatation is reversible with smoking cessation. It may be that tobacco has a direct toxic effect on the vascular endothelium. Additionally, there is growing evidence of a link between infection/inflammation and risk of coronary heart disease. A recent study showed that acute systemic inflammation induced by vaccination causes impaired endothelium dependent vasodilatation in both resistance and conduit vessels. Thus various effects on the L-arginine: nitric oxide pathway exerted by hypertension, diabetes, hyperlipidaemia, hyperhomocysteinaemia, infection/inflammation, aging, cigarette smoking, and family history of coronary heart disease may form a link between risk factors and predisposition to atherogenesis or acute events.
Alteration of the L-arginine: nitric oxide pathway in diseases: potential mechanisms
The involvement of the L-arginine: nitric oxide pathway in disease states is complex and it can be altered in several ways.
Reduced nitric oxide production
Deficiency of NOS co-factor
Several conditions are associated with NOS co-factor deficiency which may contribute to endothelial dysfunction. For instance, insulin resistance is associated with deficiency of the essential co-factor BH4, resulting in impaired vascular relaxation. Additionally, chronic cigarette smoking contributes to depletion of BH4 resulting in decreased nitric oxide synthesis, and supplementation of this co-factor restores endothelial function in chronic smokers. In hypercholesterolaemia, impaired endothelium dependent vasodilatation can also be restored with BH4supplementation, suggesting that BH4 deficiency plays an important role in impaired vascular function in these conditions.
Role of endogenous inhibitors of NOS
Overproduction of endogenous inhibitors of NOS in certain disease states may contribute to reduced nitric oxide synthesis (fig 4). Asymmetric and symmetric dimethylarginine (ADMA and SDMA) have been identified in human plasma. ADMA has properties similar to L-NMMA. It is synthesised by the human endothelial cells from arginine and is metabolised to citrulline before excretion into the urine (fig 4). The enzyme responsible for ADMA metabolism in the human vascular endothelial cells is dimethylarginine dimethylaminohydrolase of which two isoforms (DDAH I and II) have been identified, sequenced, and cloned.16 Circulating ADMA is increased in certain disease states. This includes animal models of hypertension, diabetes, hypercholesterolaemia, and atherosclerosis. In humans, raised ADMA concentrations were found in chronic renal failure,17childhood hypertension, pre-eclampsia, thrombotic microangiopathy, hypercholesterolaemia, and atherosclerosis. The mechanism whereby various disease states are associated with increased ADMA concentrations remains unclear but may involve alteration in DDAH activity, and this may be an important enzyme in atherogenesis. Accumulation of ADMA would be expected to enhance atherogenesis through loss of nitric oxide.
Reduced nitric oxide bioavailability
Role of oxidative stress
Even with adequate production, nitric oxide may not reach its biological targets (vascular smooth muscle and circulating cells) to exert its effect because of the lack of its bioavailability. For example, in hyperlipidaemia, excess LDL synthesis increases the formation of oxidised LDL. The resultant increase of oxidative stress enhances nitric oxide destruction, thereby reducing its biological effects. In atherosclerotic rabbit aorta, despite a threefold increase in total nitric oxide synthesis compared to normal rabbits, there is notably impaired endothelium dependent vasodilatation. This impaired vascular response can be partially restored following treatment with superoxide dismutase, suggesting that superoxide induced nitric oxide inactivation plays a major role. In humans, hypertriglyceridaemia with or without diabetes may have greater potential than cholesterol to increase superoxide production by leucocytes. Other atherogenic factors such as free fatty acids and low concentrations of high density lipoprotein also increase oxidative stress, contributing to reduced nitric oxide bioavailability. In addition to the associated atherogenic phenotype and oxidative stress, hyperglycaemia per se increases free radical production through increased arachidonic acid metabolism.
In human aortic endothelial cells, although prolonged exposure to high glucose concentration causes increased eNOS expression, it also leads to a concomitant increase in superoxide anion production (probably from NADH/NADPH oxidase) resulting in nitric oxide inactivation. Oxidative stress may also be a key mechanism for endothelial dysfunction in hyperhomocysteinaemia. Studies in vitro and in animals suggest that elevation of homocysteine enhances lipid peroxidation, which may contribute to impaired endothelium dependent vasodilatation. This potential mechanism is supported by the findings that the antioxidants folic acid and vitamin C rapidly reverse the impaired endothelium dependent vasodilatation without reducing the raised homocysteine concentrations. Similar improvement in endothelial function in type 2 diabetes with antioxidants such as vitamin E have also been observed, suggesting yet again the central role of oxidative stress in endothelial dysfunction under various pathophysiological conditions.
Advanced glycation endproducts
Accumulation of advanced glycation endproducts (AGEs)—the product of non-enzymatic glycation and crosslinking of collagen protein in sustained hyperglycaemia—may lead to quenching (or inactivation) of nitric oxide in diabetes. In experimentally induced diabetic rats, there is in vitro and in vivo evidence that reactive intermediates resulting from glycation quench nitric oxide rapidly. Furthermore, impairment of endothelium dependent vasodilatation in diabetic rats can be partially restored by aminoguanidine, an inhibitor of AGEs formation
Diminished vascular smooth muscle sensitivity
Vascular smooth muscle sensitivity may be decreased even with adequate nitric oxide supply. In human vascular studies, nitrovasodilators or nitric oxide donors (such as glyceryl trinitrate or sodium nitroprusside) have frequently been used as a control for agonist stimulated endothelium dependent vasodilatation. These agents act directly upon vascular smooth muscle and resultant vasodilatation is endothelium independent. There is evidence to suggest that vascular smooth muscle sensitivity to nitric oxide is reduced in diabetes and hyperglycaemia interferes with nitric oxide induced guanylate cyclase activation in vitro. Consistent with this finding, impaired vascular response to nitric oxide donors in vivo have been demonstrated in patients with type 1 diabetes.
Overproduction of nitric oxide in sepsis
Bacterial endotoxin and certain proinflammatory cytokines can lead to profound vasodilatation and decreased vasopressor responsiveness—the main clinical features of septic shock. These cardiovascular effects result from excessive nitric oxide production thought to be caused by induction of iNOS. Under normal physiological conditions, iNOS is not expressed in the vasculature. Exposure to bacterial lipopolysaccharide or proinflammatory cytokines stimulate iNOS expression. In experimental animals, administration of tumour necrosis factor α (TNFα) in doses similar to those produced endogenously during endotoxaemia rapidly results in a fall in arterial pressure, and longer exposure to TNFα and interleukin-1β (IL-1β) in vitro leads to hyporesponsiveness to vasopressors.
Several animal studies provide evidence for iNOS involvement in the pathogenesis of sepsis. Administration of bacterial lipopolysaccharide to mice causes an increase in nitrite concentration, which is attenuated by a selective iNOS inhibitor. Moreover, selective inhibition of iNOS greatly increases vascular catecholamine reactivity in experimental mice with sepsis but not in control mice. Studies in mice genetically engineered to lack the gene for iNOS also confirm the role of this isoform in septic vasodilatation. In wild type mice, treatment of carotid arteries with lipopolysaccharide leads to impaired constrictor responses which is improved with selective iNOS inhibitors. In contrast, lipopolysaccharide treatment causes no impairment of vasoconstrictor responses in carotid arteries from iNOS deficient mice.
In human sepsis the evidence for iNOS involvement has been less consistent. Some studies have suggested an increased iNOS activity—for example, in urinary leucocytes from patients with urinary tract infection, in alveolar macrophages from patients with acute respiratory distress syndrome following sepsis, and in peripheral blood mononuclear cells and macrophages isolated from putrescent muscle areas in patients with cellulitis. However, other studies have suggested the involvement of eNOS rather than iNOS in human sepsis. In an in vitro study using human umbilical vein endothelial cells cultured with IL-1β and TNFα, the resultant increase in nitric oxide production was shown to originate from eNOS as a result of activation of guanosine triphosphate cyclohydrolase (GTPCH-I), the rate limiting enzyme responsible for the synthesis of BH4. Similar findings have recently been shown in human veins in vivo. While it is clear that overproduction of nitric oxide contributes to vasodilatation in human sepsis,18 the molecular mechanisms and isoform of NOS activated are unclear. It is also not known whether inhibition of nitric oxide generation is beneficial. Expression of iNOS in active atherosclerotic plaques has also been detected. It is possible that this iNOS contributes to tissue damage or other features of plaque development or stability.
Supplementation of the nitric oxide substrate L-arginine has beneficial effects in certain conditions in laboratory animals and humans. Dietary L-arginine for 10 weeks has been shown to prevent intimal thickening in the coronary arteries and attenuates platelet reactivity in hypercholesterolaemic rabbits. Furthermore, oral L-arginine administration reduces neointimal formation following balloon catheter induced injury in both hypercholesterolaemic and normocholesterolaemic rabbit models. In humans, dietary L-arginine supplementation reduces the increased platelet reactivity in hypercholesterolaemic subjects. Additionally, intravenous L-arginine infusion reduces peripheral vascular resistance and decreases both systolic and diastolic blood pressure, at least in some studies, improves endothelium dependent coronary vasodilatation in response to intracoronary acetylcholine in hypercholesterolaemic subjects,9 and improves blood flow in critical lower limb ischaemia.
The arginine paradox
The beneficial effects of exogenous L-arginine to the vasculature in various disease states with increased plasma nitrate and cGMP concentrations during L-arginine administration suggest provision of excess L-arginine supply can stimulate NOS activity. However, it is perplexing that extracellular arginine administration should drive nitric oxide production since the intracellular arginine concentrations are always available in great excess of the needs of NOS, a phenomenon known as the “arginine paradox”. This was first demonstrated in hypercholesterolaemic rabbits19 and has also been observed in patients with pulmonary hypertension. Several explanations have been proposed to account for this paradox. Firstly, it is possible that the endogenous inhibitor of NOS, ADMA, might antagonise the normal intracellular concentrations of L-arginine, and additional arginine supplementation is required to overcome a functional defect of NOS substrate. Secondly, since eNOS is preferentially localised to specific intracellular sites known as caveolae, local concentration of L-arginine in this microenvironment may differ considerably from that within the endothelial cell. It remains unclear how specific localisation of eNOS by caveolae might affect local substrate availability, but the mechanism may involve the co-localisation of eNOS with certain arginine transporters (for example, cationic amino acid transporter-1). The formation of such a caveolar complex seems to facilitate arginine delivery to eNOS.
It is also important to recognise that the vasodilatory effects of L-arginine are not all mediated directly by nitric oxide. L-arginine may inhibit peripheral sympathetic tone leading to vasodilatation via its metabolite, agmatine, which stimulates central α2adrenoceptors. Additionally, arginine also stimulates the release of several other hormones such as glucagon, prolactin, and growth hormone which may account for its vasodilatory action. Furthermore, many of the vascular and other actions of L-arginine are shared by its stereoisomer, D-arginine, which is not a substrate for NOS. The complex mechanisms whereby L-arginine appears to improve cardiovascular function in some conditions merits further investigation.
Nitrovasodilators/nitric oxide donors
Nitrovasodilators such as amyl nitrite, glyceryl trinitrate, sodium nitroprusside, and molsidomine are all pro-drugs and exert their pharmacological effects after metabolism to nitric oxide. Hence they are termed “nitric oxide donor”. Based on their venodilatory properties, nitrovasodilators have conventionally been used for the treatment of cardiac failure and angina. Nitrosoglutathione, a compound in the class of nitrosothiols, has been studied extensively in humans. It has profound antiplatelet effects and more balanced arterial and venous vasodilatory effects than organic nitrates. Nitrosoglutathione inhibits platelet activation in the coronary artery following angioplasty and in coronary bypass grafts. Hence, nitrosothiols are potential pharmacological agents in the treatment of nitric oxide deficient conditions, and it is possible that novel nitric oxide donors could be developed that differ greatly from existing drugs.
Inhalation of nitric oxide
Administration of nitric oxide as inhalation treatment has been shown to improve several conditions affecting the pulmonary vasculature, including persistent pulmonary hypertension of the newborn, pulmonary hypertension secondary to chronic hypoxia, and adult respiratory distress syndrome (ARDS). In ARDS, selective delivery of nitric oxide to the pulmonary vasculature reduces the pulmonary arterial pressure and increases arterial oxygenation by improving the matching of ventilation with perfusion. As the nitric oxide is rapidly inactivated by haemoglobin, inhalation of nitric oxide gas does not cause systemic vasodilatation. However, whether this form of nitric oxide treatment will improve survival in patients with ARDS remains to be determined by randomised controlled clinical trials. It does have potential adverse effects such as pulmonary oedema and methaemoglobinaemia. There are as yet no clear guidelines regarding the effective dose of inhaled nitric oxide for the above pulmonary conditions.
Since oxidative stress has been strongly implicated in endothelial dysfunction, numerous studies have examined the role of antioxidants in vascular function and in the prevention of cardiovascular disease. Intrabrachial administration of ascorbic acid (vitamin C) improves endothelium dependent vasodilatation in patients with type 2 diabetes, smokers, patients with hypercholesterolaemia, and patients with heart failure. Similarly, oral administration of ascorbic acid in patients with coronary heart disease also improves flow mediated vasodilatation. This beneficial effect has been shown to occur rapidly after two hours and can be sustained for 30 days. Furthermore, intravenous infusion of ascorbic acid improved endothelium dependent vasodilatation in epicardial arteries in hypertensive patients without coronary heart disease. In patients with coronary heart disease, intracoronary co-infusion of vitamin C with L-arginine causes greatly increased vasodilatation. Despite these observations, not all experiments have shown beneficial effects and further studies are required. In addition, agents such as vitamin C can produce pro-oxidant effects in some circumstances.
The direct transfer of NOS isoform genes to the vessel wall alters vasomotor function and may have a role in the treatment of cardiovascular diseases.20 This approach has been shown to be effective in a variety of animal models of vascular disease. Vascular gene therapy of eNOS delivered to specific tissues enhances nitric oxide production at the site of interest. In 1995, NOS gene transfer was first reported when eNOS cDNA, in a complex with the haemagglutinating virus of Japan, was delivered to rat carotid arteries intraluminally following balloon injury. This resulted in a pronounced reduction in neointima formation at 14 days. Shortly after, similar results were confirmed by other research groups in iliac and coronary arteries and vein grafts. Gene therapy has also been extended from local to systemic delivery. Delivery of a single injection of naked eNOS cDNA into the systemic circulation through the tail vein of spontaneously hypertensive rats resulted in increased production and excretion of cGMP and nitrite/nitrate, and was associated with a significant reduction in systolic blood pressure lasting up to 12 weeks.
Inhibition of iNOS has been shown to improve nitric oxide mediated haemodynamic changes in experimental models of septic shock.18 Intravenous administration of the arginine analogue L-NMMA reverses the decrease in peripheral vascular resistance and fall in arterial blood pressure in endotoxaemic dogs. The same effects with L-NMMA have also been confirmed in humans in a randomised, double blind, placebo controlled trial.18 A potential pitfall in this therapeutic strategy is that none of the currently available NOS inhibitors are specific for the excess nitric oxide causing pathophysiology, and may therefore lead to potential hazardous effects, by also inhibiting “physiological” nitric oxide. Indeed, both pulmonary hypertension and reduced cardiac output have been reported following NOS inhibition. Future drug development in this area should focus on NOS isoform specificity as well as the degree of inhibition required in order to produce an optimal pharmacological effect.
Nitric oxide is a major player in cardiovascular physiology and pharmacology. Its release from endothelium exerts a tonic hypotensive, antiplatelet, antiatherogenic influence in the arterial tree. Several common cardiovascular disease states or risk factors impair nitric oxide synthesis, increase nitric oxide destruction or affect the ability of cells to respond to this mediator. The net effect is to enhance vascular tone and reactivity and predispose to atherosclerosis. Clinicians already use drugs that either mimic nitric oxide (nitric oxide donors) or enhance its endogenous production (for example, by lowering blood pressure or serum cholesterol). In contrast, overproduction of nitric oxide is an important mechanism of inflammatory vasodilatation. Over the next few years a new generation of drugs will emerge that specifically modify nitric oxide production or mimic its action. Indeed, the first such drug is sildenafil which blocks the phosphodiesterase that degrades cGMP and thereby acts as an amplifier of nitric oxide signalling (fig 1). Diagnostic tests based on early assessment of endothelial function may also become part of cardiovascular risk stratification or assessment of novel therapeutics.
Endothelium derived nitric oxide has important antiatherogenic properties:
enhancement of vasodilatation
inhibition of platelet aggregation
inhibition of leucocyte migration
inhibition of smooth muscle proliferation and migration
inhibition of adhesion molecule activation and expression
Three distinct nitric oxide synthase isoforms exist which all have a role in vascular control under different conditions
Reduced nitric oxide synthesis or defective nitric oxide activities predispose to atherosclerosis
Different disease processes and risk factors affects the L-arginine–nitric oxide pathway via different mechanisms:
decreased co-factor availability
decreased enzyme expression/activity
increased endogenous nitric oxide synthase inhibitors
decreased nitric oxide bioavailability
decreased vascular smooth muscle sensitivity to nitric oxide
Understanding these mechanisms in diseases may help therapeutic strategies in prevention of atherosclerosis
This work is supported by the British Heart Foundation.
- Additional references for "Endothelial function and nitric oxide: clinical relevance" by Vallance and Chan. Heart 2001;85:342-350
- Anastasiou E, Lekakis JP, Alevizaki M, et al. Impaired endothelial-dependent vasodilatation in women with previous gestational diabetes. Diabetes Care 1998;21:111-15.
- Anderson TJ, Uehata A, Gerhard MD, et al. Endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995;26:1235-41.
- Angus JA, Cocks TM, McPherson GA, et al. The acetylcholine paradox:a constrictor of human small coronary arteries even in the presence of endothelium. Clin Exp Pharmacol Physiol 1991;18:33-6.
- Baylis C, Vallance P. Measurement of nitric oxide and nitrate levels in plasma and urine - what does this measure tell us about the activity of the endogenous nitric oxide system? Curr Opin Nephrol Hypertens 1998;7:50-62.
- Bellamy MF, McDowell IFW, Ramsey MW, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998;98:1848-52.
- Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in humans, in vivo. Circulation 1997;96:3042-7.
- Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a noval risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998;98:1842-7.
- Bucala R, Tracey KL, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991;87:432-8.
- Busse R, Mulsch A, Fleming I, Hecker M. Mechanisms of nitric oxide release from the vascular endothelium. Circulation 1993;87:V18-25.
- Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548-54.
- Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149-55.
- Celermajer DS. Endothelial dysfunction: Does it matter? Is it reversible? J Am Coll Cardiol 1997;30:325-33.
- Chataigneau T, Feletou M, Huang PL, et al. Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol 1999;126:219-26.
- Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 1992;90:1116-21.
- Clarkson P, Celermajer DS, Powe AJ, et al. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997;96:3378-83.
- Cockcroft JR, Chowienczyk PJ, Benjamin N, et al. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994;330:1036-40.
- Collier J, Vallance P. Biphasic response to acetylcholine in human hand veins in vivo: the role of the endothelium. Clin Sci 1990;78:101-4.
- Cooke JP, Andon NA, Girerd WJ, et al. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation 1991;83:1057-62.
- Corson MA, James NL, Latta SE, et al. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Cir Res 1996;79:984-91.
- Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolaemic humans. J Clin Invest 1990;86:228-34.
- Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioavailability, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/ angiotensin II conversion in patients with chronic failure. Circulation 2000;101:594-7.
- Fleming I, Bauersachs J, Fisslthaler B, et al. Calcium-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ Res 1998;82:686-95.
- Forte P, Copland M, Smith LM, et al. Basal nitric oxide synthesis in essential hypertension. Lancet 1997;349:837-42.
- Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic gaunosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
- Janssens S, Flaherty D, Nong Z, et al. Human endothelial nitric oxide gene transfer inhibits vascular vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 1998;97:1274-81.
- Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-19.
- Kawagishi T, Matsuyoshi M, Emoto M, et al. Impaired endothelial-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 1999;19:2509-16.
- Lansman JB, Hallam TJ, Rink TJ. Single stretch-activated ion channels in vascular endothelial cells as mechanotransducers? Nature 1987;325:811-13.
- Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93:1107-13.
- Lewis TV, Dart AM, Chin-Dusting JP. Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. J Am Coll Cardiol 1999;33:805-12.
- MacAllister RJ, Calver AL, Collier J, et al. Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effects? Clin Sci (Colch) 1995;89:183-90.
- Makimattila S, Mantysaari M, Groop P-H, et al. Hyperreactivity to nitrovasodilators in forearm vasculature is related to autonomic dysfunction in insulin-dependent diabetes mellitus. Circulation 1997;95:618-25.
- Naruse K, Shimizu K, Muramatsu M, et al. Long-term inhibition of NO synthesis promotes atherosclerosis in the hyperchoolesrterolemic rabbit thoracic aorta. Arterioscler Thromb 1994;14:746-52.
- Nava E, Palmer RMJ, Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet 1991;338:1555-7.
- Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997;129:111-18.
- Panza JA, Casino PR, Kilcoyne CM, et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993;87:1468-74.
- Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-4.
- Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994;28:34-9.
- Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N Engl J Med 1999;341:709-17.
- Quyyumi AA, Dakak N, Andrews NP, et al. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995;92:320-6.
- Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375-8.
- Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-405.
- Schachinger Schachinger, Halle M, et al. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 1998;30:927-34.
- Schoeffter P, Dion R, Godfraind T. Modulatory role of the vascular endothelium in the contractility of human isolated internal mammary artery. Br J Pharmacol 1988;95:531-43.
- Stroes E, deBruin T, deValk H, et al. NO activity in familial combined hyperlipidaemia: potential role of cholesterol remants. Cardiovasc Res 1997;36:445-52.
- Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin dependent diabetes mellitus. J Clin Invest 1996;97:22-8.
- Werns SW, Walton JA, Hsia HH, et al. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989;79:287-91.
- Yasue H, Matsuyama K, Okumura K, et al. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment. Posible role of early coronary atherosclerosis. Circulation 1990;81:482-90.
- Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000;102:994-9.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.